Literature DB >> 2936943

Intranasal administration of alpha-human natriuretic peptide produces a prolonged diuresis in healthy man.

H Shionoiri, Y Kaneko.   

Abstract

The effects of an intranasal administration of synthetic alpha-human natriuretic polypeptide (alpha-hANP) were studied in 8 healthy male volunteers. They were given an intranasal administration of alpha-hANP at doses of 0.56-0.62 microgram/kg twice in the same day, the first and second administrations being separated by 180 min. Urine volume and urinary sodium excretion increased 2 to 3-fold 60 min after each administration. There were no significant changes in blood pressure, heart rate, glomerular filtration rate, plasma renin activity and plasma concentration of aldosterone, cortisol and catecholamines. The intranasal administration of alpha-hANP was well tolerated by the volunteers, and no untoward effect was observed. The results suggest that alpha-hANP can be used as a nasal spray in patients with overhydration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936943     DOI: 10.1016/0024-3205(86)90593-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

Review 1.  Atrial natriuretic factor: a hormone secreted by the heart.

Authors:  D D Macchia
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

Review 2.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

Review 3.  Atrial natriuretic peptides: clues to their physiological and clinical importance.

Authors:  D R Singer
Journal:  Postgrad Med J       Date:  1987-01       Impact factor: 2.401

4.  Renal and hormonal effects and tolerance of an ANP analogue in healthy man.

Authors:  H Eiskjaer; M Schmiegelow; B Jespersen; I N Tietze; J D Jensen; S S Sørensen; K Thomsen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.